XML 40 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2016
Segment Information  
Schedule of segment information - net sales and operating earnings

 

 

 

Net Sales to External Customers

 

Operating Earnings

 

 

 

Three Months

 

Six Months

 

Three Months

 

Six Months

 

 

 

Ended June 30

 

Ended June 30

 

Ended June 30

 

Ended June 30

 

(in millions)

 

2016

 

2015

 

2016

 

2015

 

2016

 

2015

 

2016

 

2015

 

Established Pharmaceutical Products

 

$
980

 

$
977

 

$
1,868

 

$
1,874

 

$
192

 

$
172

 

$
340

 

$
339

 

Nutritional Products

 
1,740

 
1,717

 
3,411

 
3,386

 
368

 
389

 
710

 
739

 

Diagnostic Products

 
1,226

 
1,177

 
2,344

 
2,270

 
288

 
304

 
555

 
580

 

Vascular Products

 
782

 
722

 
1,467

 
1,420

 
290

 
280

 
537

 
564

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Reportable Segments

 
4,728

 
4,593

 
9,090

 
8,950

 
1,138

 
1,145

 
2,142

 
2,222

 

Other

 
605

 
577

 
1,128

 
1,117

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$
5,333

 

$
5,170

 

$
10,218

 

$
10,067

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate functions and benefit plans costs

 

 

 

 

 

 

 

 

 
(94

)
(104

)
(175

)
(221

)

Non-reportable segments

 

 

 

 

 

 

 

 

 
52

 
62

 
50

 
117

 

Net interest expense

 

 

 

 

 

 

 

 

 
(83

)
(17)

 
(108

)
(33

)

Share-based compensation (a)

 

 

 

 

 

 

 

 

 
(62

)
(57

)
(214

)
(205

)

Amortization of intangible assets

 

 

 

 

 

 

 

 

 
(145

)
(151

)
(289

)
(307

)

Other, net (b)

 

 

 

 

 

 

 

 

 
(91

)
108

 
(689

)
66

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings from continuing operations before taxes

 

 

 

 

 

 

 

 

 

$
715

 

$
986

 

$
717

 

$
1,639

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net for the six months ended June 30, 2016, includes $477 million of foreign currency loss related to operations in Venezuela. Other, net for the three months and six months ended June 30, 2015, includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.